Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. (2019)

First Author: Barone M
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjh.15682

PubMed Identifier: 30450539

Publication URI: http://europepmc.org/abstract/MED/30450539

Type: Journal Article/Review

Volume: 185

Parent Publication: British journal of haematology

Issue: 5

ISSN: 0007-1048